论文部分内容阅读
目的:研究不同阶段应用拉米夫定对激素诱导的乙肝病毒再激活的影响。方法:将接受激素治疗的患者分为两组。预防给药组即激素治疗初始阶段患者无明显HBV复制活跃;延期给药组患者接受激素治疗后检查发现HBV-DNA升高10倍以上或其绝对值>109拷贝/ml。对炎症再活动发生率、肝功能失代偿发生率、存活率、综合治疗有效率进行比较。结果:两组炎症再活动发生率、肝功能失代偿发生率、存活率、综合治疗有效率比较,差异均具有显著性。结论:预防性给药可以降低炎症再活动发生率、肝功能失代偿发生率,提高存活率、综合治疗有效率。
Objective: To study the effect of lamivudine on hormone-induced reactivation of hepatitis B virus in different stages. Methods: Patients receiving hormone therapy were divided into two groups. In the prophylaxis group, there was no significant HBV replication in the initial stage of hormone therapy. Patients in the deferment group showed a 10-fold increase in HBV-DNA or> 109 copies / ml after hormone therapy. The incidence of inflammatory reactivation, the incidence of decompensated liver function, survival rate, the comprehensive treatment efficiency were compared. Results: The incidence of inflammatory reactivation, incidence of hepatic decompensation, survival rate, and comprehensive treatment efficiency were significantly different between the two groups. Conclusion: Preventive administration can reduce the incidence of inflammatory reactivation, the incidence of hepatic decompensation, improve the survival rate and the comprehensive treatment efficiency.